SCHEMBL200925

SCHEMBL200925

COC(=O)C1CSCN1C(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.46
HSD17B10 Q99714 3/20 0.45
NPSR1 Q6W5P4 1/20 0.45
PTPN1 P18031 1/20 0.41
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.36
USP2 O75604 1/20 0.36
DPP4 P27487 1/20 0.34
DPP8 Q6V1X1 1/20 0.34
DPP7 Q9UHL4 1/20 0.34
CHRM2 P08172 1/20 0.34
CHRM1 P11229 1/20 0.34
CHRM3 P20309 1/20 0.34
NPC1 O15118 1/20 0.34
PREP P48147 1/20 0.34
IMPDH2 P12268 3/20 0.34
SCN4A P35499 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL200923 1.00 ATM (0.46) ATMHSD17B10NPSR1PTPN1NR1H2
SCHEMBL26077743 0.90 ATM (0.45) ATMHSD17B10NPSR1NR1H2SMN1; SMN2
SCHEMBL337199 0.85 NR1H2 (0.42) ATMHSD17B10NPSR1PTPN1NR1H2
SCHEMBL18745636 0.85 NR1H2 (0.42) ATMHSD17B10NPSR1PTPN1NR1H2
SCHEMBL202300 0.84 ACE (0.48) ATMHSD17B10SMN1; SMN2USP2CHRM2
SCHEMBL202301 0.84 ACE (0.48) ATMHSD17B10SMN1; SMN2USP2CHRM2
SCHEMBL14237836 0.84 ATM (0.45) ATMHSD17B10NR1H2SMN1; SMN2USP2
SCHEMBL16187224 0.84 ATM (0.45) ATMHSD17B10NR1H2SMN1; SMN2USP2
SCHEMBL1022969 0.84 ACE (0.48) ATMHSD17B10SMN1; SMN2USP2CHRM2
SCHEMBL12158525 0.83 ATM (0.45) ATMHSD17B10SMN1; SMN2USP2DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111170938-A 5, 6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists 豪夫迈·罗氏有限公司 2020-05-19 CN disclosed
EP-3126349-B1 5,6-DISUBSTITUTED PYRIDINE-2-CARBOXAMIDES AS CANNABINOID RECEPTOR AGONISTS HOFFMANN LA ROCHE (CH) 2019-06-26 EP disclosed
EP-3126349-B1 5,6-DISUBSTITUTED PYRIDINE-2-CARBOXAMIDES AS CANNABINOID RECEPTOR AGONISTS HOFFMANN LA ROCHE (CH) 2019-06-26 EP disclosed
US-20180327360-A1 NOVEL PYRIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2018-11-15 US disclosed
EP-2928868-B1 PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS HOFFMANN LA ROCHE (CH) 2017-08-09 EP disclosed
EP-3126349-A1 5,6-DISUBSTITUTED PYRIDINE-2-CARBOXAMIDES AS CANNABINOID RECEPTOR AGONISTS F. Hoffmann-La Roche AG (CH) 2017-02-08 EP disclosed
US-20160376237-A1 NOVEL PYRIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2016-12-29 US disclosed
US-9303012-B2 Pyridine-2-amides useful as CB2 agonists HOFFMAN-LA ROCHE INC. (US) 2016-04-05 US disclosed
US-20150299165-A1 PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS HOFFMANN-LA ROCHE INC. (US) 2015-10-22 US disclosed
EP-2928868-A1 PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS F. Hoffmann-La Roche AG (CH) 2015-10-14 EP disclosed
WO-2015150438-A1 5,6-DISUBSTITUTED PYRIDINE-2-CARBOXAMIDES AS CANNABINOID RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2015-10-08 WO disclosed
WO-2014086806-A1 PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2014-06-12 WO disclosed
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 US disclosed
EP-2338878-A2 N-hydroxyamide derivatives possessing antibacterial activity Vicuron Pharmaceuticals, Inc. (US) 2011-06-29 EP disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 US disclosed
EP-1963262-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2008-09-03 EP disclosed
WO-2007069020-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299165-A1 PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS CNR2, CNR1, GPR52 ATM 3396/4885HSD17B10 3567/4885NPSR1 34/4885
US-20160376237-A1 NOVEL PYRIDINE DERIVATIVES NDUFS6, NDUFS4, NDUFV1 ATM 2080/4885HSD17B10 2413/4885NPSR1 132/4885
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY NAAA, HDHD5, HACL2 ATM 4519/4885HSD17B10 111/4885NPSR1 1561/4885
US-20180327360-A1 NOVEL PYRIDINE DERIVATIVES NDUFS6, NDUFS4, NDUFV1 ATM 2080/4885HSD17B10 2413/4885NPSR1 132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.